Browsing Tag
ASC47
2 posts
Is Ascletis Pharma quietly building an Asian obesity pipeline rival to Novo Nordisk and Eli Lilly?
Ascletis Pharma is building an obesity pipeline with ASC47 and ASC30. Can this dual-pathway approach rival Novo Nordisk and Eli Lilly?
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.